Developer docs
API playgroundTry for free, no card

Search company profiles

Immutep

Full company profile

uuid0003b9a

Namestring
Immutep
Legal namestring
Immutep Limited
Websiteurl
immutep.com
Company typeenum
Public
Founded yearint
2001
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
LAG-3 immunotherapy, oncology drug development, autoimmune disease therapy, clinical-stage biotechnology, cancer immunotherapy
Industry3 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Immuno-oncology biotechnology
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Immutep receives upfront payments, regulatory milestones, development milestones, and commercial milestone payments from licensing partners. For example, Dr. Reddy's deal includes $20 million upfront and up to $349.5 million in milestones plus royalties.

biotechdispatch.com.au
2Royalty Revenue
TypeLicensing Royalties
Description

Future royalty payments on net sales of licensed products in partner territories, including double-digit royalties from Dr. Reddy's on commercial sales.

biotechdispatch.com.au
3Manufacturing Rights Retention
TypeLicensing Royalties
Description

Immutep retains global manufacturing rights for efti, providing potential for manufacturing revenue if products are approved and commercialized.

immutep.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1No commercial products available for pricing
ModelOtherBilling cadenceOther
Notes

Immutep is in late clinical-stage development with no approved products on the market as of the data available. Pricing will be determined upon regulatory approval and commercialization.

biospace.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Immutep develops clinical-stage immunotherapy drug candidates based on LAG-3 (Lymphocyte Activation Gene-3) biology for the treatment of cancer and autoimmune diseases. Its lead asset, eftilagimod alfa (efti), is a soluble LAG-3 protein and MHC Class II agonist administered subcutaneously to activate antigen-presenting cells in oncology indications such as NSCLC, HNSCC, breast cancer, and soft tissue sarcoma. The company also develops IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, and earns revenue by licensing its candidates to pharmaceutical partners while retaining manufacturing rights.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 51.5% median tumor hyalinization/fibrosis in soft tissue sarcoma patients (exceeding 35% target)
+3 more records
Product overview1 text field

Immutep is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The company's diversified portfolio harnesses LAG-3's ability to stimulate immune response to fight cancer or modulate it to combat autoimmune diseases. The primary focus centers on two proprietary first-in-class therapeutics: eftilagimod alfa (efti) in oncology and IMP761 in autoimmune diseases. The company has four clinical-stage candidates and one early research-stage candidate. Eftilagimod alfa works as a soluble LAG-3 protein and MHC Class II agonist that uniquely activates antigen-presenting cells, while IMP761 is the world's first LAG-3 agonist antibody for autoimmune diseases. Additional assets include IMP731 (LAG-3 depleting antibody) and LAG525 which has been out-licensed to Novartis.

Product and service4 records
1Eftilagimod alfa (efti)
CategoryOncology immunotherapy drug candidate (APC activator)
Description

Eftilagimod alfa (efti) is a first-in-class soluble LAG-3 protein and MHC Class II agonist administered subcutaneously that activates antigen-presenting cells (APCs), stimulating both innate and adaptive immune responses for cancer treatment. It is being evaluated in combination with pembrolizumab and chemotherapy in NSCLC, HNSCC, breast cancer, and soft tissue sarcoma.

2IMP761
CategoryAutoimmune disease immunotherapy drug candidate (LAG-3 agonist)
Description

IMP761 is a first-in-class LAG-3 agonist antibody for autoimmune diseases that acts upstream on activated T cells to target the root cause of autoimmune diseases and restore immune system balance. Phase I study showed dose-dependent immunosuppressive effects in healthy volunteers.

3IMP731
CategoryAutoimmune disease immunotherapy drug candidate (LAG-3 depleting antibody)
Description

IMP731 is a LAG-3 depleting antibody that eliminates T cells to combat autoimmune diseases. It has been tested in Phase II in active ulcerative colitis and a Phase I/Ib trial in psoriasis.

4LAG525 (ieramilimab)
CategoryOncology immunotherapy drug candidate (anti-LAG-3 antibody, licensed)
Description

LAG525 (ieramilimab) is an anti-LAG-3 antibody clinical candidate developed by Immutep and licensed to Novartis, which has full responsibility for continued development and commercialization. Immutep is eligible for development-based milestone payments and royalties on net sales.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Exclusive licensing and collaboration agreement for development and commercialization of eftilagimod alfa (efti) across most global markets outside North America, Europe, Japan, and Greater China. Immutep received $20 million upfront and is eligible for up to $349.5 million in regulatory, development, and commercial milestone payments, plus double-digit royalties on future sales. Immutep retains global manufacturing rights.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration and supply agreement to evaluate combination of efti with KEYTRUDA (pembrolizumab) in multiple solid tumors including non-small cell lung cancer, head and neck cancer, and ovarian cancer (TACTI-002 trial).

3Merck KGaA (Darmstadt, Germany)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial collaboration and supply agreement for combination therapies in oncology.

immutep.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

License agreement for LAG525 (ieramilimab), an anti-LAG-3 antibody. Novartis has full responsibility for continued development and commercialization. Immutep eligible for development-based milestone payments and royalties on sales. Two patent families co-owned with Novartis.

5EOC Pharma
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

License agreement for eftilagimod alfa in Greater China (Hong Kong, Macau, Taiwan). EOC Pharma is an oncology-focused affiliate of Eddingpharm. Immutep received milestone payment and will receive royalties on net sales.

immutep.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immutep

Immuno-oncology biotechnologyimmutep.com

Immutep firmographics

Firmographics
Name
Immutep
Legal name
Immutep Limited
Website
https://immutep.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Immutep industry classification

Industry
Product category
Immuno-oncology biotechnology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • LAG-3 immunotherapy
  • Oncology drug development
  • Autoimmune disease therapy
  • Clinical-stage biotechnology
  • Cancer immunotherapy

Where Immutep is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices4 records

Markets served

Immutep business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing and Milestone Payments: Immutep receives upfront payments, regulatory milestones, development milestones, and commercial milestone payments from licensing partners. For example, Dr. Reddy's deal includes $20 million upfront and up to $349.5 million in milestones plus royalties.
  2. Royalty Revenue: Future royalty payments on net sales of licensed products in partner territories, including double-digit royalties from Dr. Reddy's on commercial sales.
  3. Manufacturing Rights Retention: Immutep retains global manufacturing rights for efti, providing potential for manufacturing revenue if products are approved and commercialized.

Pricing tiers

ModelBillingPrice
OtherOtherNo commercial products available for pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Immutep product offering

Product offering

Core offering

Immutep develops clinical-stage immunotherapy drug candidates based on LAG-3 (Lymphocyte Activation Gene-3) biology for the treatment of cancer and autoimmune diseases. Its lead asset, eftilagimod alfa (efti), is a soluble LAG-3 protein and MHC Class II agonist administered subcutaneously to activate antigen-presenting cells in oncology indications such as NSCLC, HNSCC, breast cancer, and soft tissue sarcoma. The company also develops IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, and earns revenue by licensing its candidates to pharmaceutical partners while retaining manufacturing rights.

Product overview

Immutep is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The company's diversified portfolio harnesses LAG-3's ability to stimulate immune response to fight cancer or modulate it to combat autoimmune diseases. The primary focus centers on two proprietary first-in-class therapeutics: eftilagimod alfa (efti) in oncology and IMP761 in autoimmune diseases. The company has four clinical-stage candidates and one early research-stage candidate. Eftilagimod alfa works as a soluble LAG-3 protein and MHC Class II agonist that uniquely activates antigen-presenting cells, while IMP761 is the world's first LAG-3 agonist antibody for autoimmune diseases. Additional assets include IMP731 (LAG-3 depleting antibody) and LAG525 which has been out-licensed to Novartis.

Differentiator

Problem solved

Functional benefit

Products and services

  • Eftilagimod alfa (efti) Eftilagimod alfa (efti) is a first-in-class soluble LAG-3 protein and MHC Class II agonist administered subcutaneously that activates antigen-presenting cells (APCs), stimulating both innate and adaptive immune responses for cancer treatment. It is being evaluated in combination with pembrolizumab and chemotherapy in NSCLC, HNSCC, breast cancer, and soft tissue sarcoma.
  • IMP761 IMP761 is a first-in-class LAG-3 agonist antibody for autoimmune diseases that acts upstream on activated T cells to target the root cause of autoimmune diseases and restore immune system balance. Phase I study showed dose-dependent immunosuppressive effects in healthy volunteers.
  • IMP731 IMP731 is a LAG-3 depleting antibody that eliminates T cells to combat autoimmune diseases. It has been tested in Phase II in active ulcerative colitis and a Phase I/Ib trial in psoriasis.
  • LAG525 (ieramilimab) LAG525 (ieramilimab) is an anti-LAG-3 antibody clinical candidate developed by Immutep and licensed to Novartis, which has full responsibility for continued development and commercialization. Immutep is eligible for development-based milestone payments and royalties on net sales.

Quantifiable outcome

  • 51.5% median tumor hyalinization/fibrosis in soft tissue sarcoma patients (exceeding 35% target)
  • +3 more outcomes

Companies that use Immutep

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Immutep technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Immutep partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Dr. Reddy's LaboratoriescoreStrategic or Co-development Partner · 8 December 2025Exclusive licensing and collaboration agreement for development and commercialization of eftilagimod alfa (efti) across most global markets outside North America, Europe, Japan, and Greater China. Immutep received $20 million upfront and is eligible for up to $349.5 million in regulatory, development, and commercial milestone payments, plus double-digit royalties on future sales. Immutep retains global manufacturing rights.
  • MSD (Merck US)coreStrategic or Co-development PartnerClinical trial collaboration and supply agreement to evaluate combination of efti with KEYTRUDA (pembrolizumab) in multiple solid tumors including non-small cell lung cancer, head and neck cancer, and ovarian cancer (TACTI-002 trial).
  • Merck KGaA (Darmstadt, Germany)minorStrategic or Co-development PartnerClinical trial collaboration and supply agreement for combination therapies in oncology.
  • NovartiscoreOEM/ Whitelabel/ Licensing PartnerLicense agreement for LAG525 (ieramilimab), an anti-LAG-3 antibody. Novartis has full responsibility for continued development and commercialization. Immutep eligible for development-based milestone payments and royalties on sales. Two patent families co-owned with Novartis.
  • EOC PharmacoreOEM/ Whitelabel/ Licensing PartnerLicense agreement for eftilagimod alfa in Greater China (Hong Kong, Macau, Taiwan). EOC Pharma is an oncology-focused affiliate of Eddingpharm. Immutep received milestone payment and will receive royalties on net sales.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Immutep competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Immutep social profiles

Digital presence

Immutep compliance and trust

Trust signal

Compliance3 records

Immutep financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immutep leadership team

Management profile

Number of profiles

Profiles17 records

Immutep subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Immutep funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immutep M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immutep

What does Immutep do?

Immutep develops clinical-stage immunotherapy drug candidates based on LAG-3 (Lymphocyte Activation Gene-3) biology for the treatment of cancer and autoimmune diseases. Its lead asset, eftilagimod alfa (efti), is a soluble LAG-3 protein and MHC Class II agonist administered subcutaneously to activate antigen-presenting cells in oncology indications such as NSCLC, HNSCC, breast cancer, and soft tissue sarcoma. The company also develops IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, and earns revenue by licensing its candidates to pharmaceutical partners while retaining manufacturing rights.

Is Immutep a public or private company?

Immutep is a public company. It is classified as public and is currently operating.

When was Immutep founded?

Immutep was founded in 2001. It employs 51 to 100 people.

Where is Immutep based?

Immutep is headquartered in Sydney, Australia, in the Oceania region.

How does Immutep make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are royalty Revenue and manufacturing Rights Retention.

Does Immutep have an API?

No public API is recorded for Immutep.

What industry is Immutep in?

Immutep's product category is Immuno-oncology biotechnology. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewImmutep Limited (IMM) Reports 81.1% DFS at 12 Months in Phase II TrialImmutep reported 81.1% disease-free survival at 12 months in the EFTISARC-NEO Phase II trial for resectable soft tissue sarcoma. Subgroup analysis showed 95.0% DFS for patients with high TIL levels versus 64.9% for lower levels. The 18-month estimate remains immature, with a registration-directed trial planned for H2 2027.Business & FinancialImmutep Reports Encouraging Disease-Free Survival From EFTISARC-NEO Phase II Trial In Soft Tissue SarcomaImmutep reported 12-month disease-free survival of 81.1% and 18-month disease-free survival of 81.1% from the EFTISARC-NEO Phase II trial in soft tissue sarcoma. Exploratory analyses linked higher post-treatment tumour-infiltrating lymphocytes and hyalinisation/fibrosis to better survival. The company plans to report additional data in CY2027 and advance efti into a registration-directed trial in H2 CY2027.The future of tradingImmutep's IMP761 Shows Significant Suppression of T-Cell Immune Responses in Phase I TrialImmutep announced positive Phase I results for IMP761 in healthy volunteers, presented at ACR Convergence 2026. A single infusion significantly suppressed T-cell-driven immune responses, with stronger effects at higher drug exposure, and the drug was well tolerated across seven dose levels. Multiple-dose phase results are expected in the first half of 2027 to guide dose selection for a potential Phase II program.The future of tradingImmutep Publishes Presentation on IMP761 Phase I StudyImmutep published a presentation on its LAG-3 agonist antibody IMP761, including interim Phase 1 results from a placebo-controlled study in 60 healthy volunteers. The study showed significant, exposure-dependent suppression of KLH-induced immune responses, with the drug well tolerated across doses and no severe or serious adverse events. Pharmacokinetic findings support dosing every four weeks at higher dose levels of 2.5-14 mg/kg.Business & FinancialImmutep Announces Upcoming Poster Presentations At CTOS 2026 And ESMO Immuno-Oncology & Advanced Therapies Congress 2026Immutep will present poster data from its Eftisarc-Neo Phase II trial and TACTI-003 Part B study at CTOS 2026 and ESMO 2026. The presentations cover DFS in resectable soft tissue sarcoma and first-line recurrent head and neck cancer, with data available on the company's website after the sessions.Business & FinancialImmutep Receives A$2.16 Million French R&D Tax IncentiveImmutep received A$2.16 million in French R&D tax incentive funding via its French subsidiary, following an A$0.86 million Australian rebate. The non-dilutive funding will support R&D on product candidates eftilagimod alfa and IMP761, with expected cash reach extending into the first half of CY2028.Business & FinancialImmutep Announces Late-Breaking Abstract On IMP761 Accepted For Poster Presentation At ACR Convergence 2026Immutep announced a late-breaking abstract on IMP761, a LAG-3 agonist antibody, for poster presentation at ACR Convergence 2026. The trial IMP761-P001 (NCT06637865) will be presented on November 10, 2026, with preclinical data published in J Immunology and Pediatric Research.The future of tradingImmutep to Present IMP761 Phase I Trial Data at ACR Convergence 2026Immutep will present Phase 1 data on IMP761 at ACR Convergence in Orlando on November 10, 2026, following late-breaking abstract acceptance. The first-in-human trial evaluates the immunosuppressive LAG-3 agonist antibody in healthy volunteers using a randomized, placebo-controlled, double-blind design. Initial interim results were presented at the EULAR 2026 Congress in June 2026.The future of tradingImmutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive DirectorPete Meyers has resigned as Deputy Chairman and Non-Executive Director of Immutep Ltd, effective October 2, 2026. The resignation is announced by the company, with no further details provided.Seeking AlphaImmutep announces 1-for-20 ADS ratio change (NASDAQ:IMMP)Immutep will change its American Depositary Share (ADS) ratio from one ADS equaling ten ordinary shares to one ADS equaling 200 ordinary shares. This adjustment is equivalent to a 1-for-20 reverse split and will take effect on September 28, 2026.